TEHRAN, Sep. 06 (MNA) – Biotechnology Research Center (Zist Fanavari) has launched development of 3 recombinant medicines including for MS and Alzheimer’s disease.

Azin Mehrdad, the head of Biotechnology Research Center in Iranian Research Organization for Science and Technology told Mehr News that the Center was working on development of three medicines from herbal recombinant products. “Calcitonin Recombinant Protein is a hormonal medicine which helps calcium sedimentation in bones and thus may function in preventing osteoporosis, which has recently been in rise across the country. “The research to develop the medicine had been launched 5 years ago; however, problems delayed the production of the medicine,” he added.


“The Research Center seeks to develop recombinant MGF (Mechano Growth Factor); the medicine is administered for patients with brain cell and neurons loss, such as Alzheimer’s and MS diseases,” Mehrdad said, adding that the medicine was in its experimental phase yet.


“Testing medicines on human, animal and cell culture is time consuming and needs human volunteers; we launched research on MGF 18 months ago,” Mehrdad said.


“According to figures by Ministry of Health, cervical cancer is on rise among women, where a virus is the major contributing factor; to fight the virus, in cooperation with Pasteur Institute, the Center is working on a vaccine to treat this cancer,” he maintained. “The vaccine is mandatory for female teens above 14 in the EU, while in Iran it is imported and we should produce the vaccine inside the country,” he added.


By Mehr News Agency





The Iran Project is not responsible for the content of quoted articles.